Efficacy of nerve growth factor antibody in a knee osteoarthritis pain model in mice

Masayuki Miyagi¹*, Tetsuhiro Ishikawa², Hiroti Kamoda², Miyako Suzuki², Gen Inoue¹, Yoshihiro Sakuma², Yasuhiro Oikawa², Sumihisa Orita², Kentaro Uchida¹, Kazuhisa Takahashi², Masashi Takaso¹ and Seiji Ohtori²

Abstract

Background: Nerve growth factor (NGF) is not only an important factor in nerve growth but also a major contributor to the production of inflammation. It has been reported that inhibiting NGF could reduce several types of pain in several animal models. Here, we aimed to clarify the efficacy of NGF antibody in a knee osteoarthritis (OA) pain model in mice.

Method: Six-week-old male C57BR/J mice were used (n = 30). Ten mice comprised the control group, which received saline injection into the right knee joints; the other 20 mice comprised the experimental group, which received monoiodoacetate (MIA) injection into the right knee joints. Three weeks after surgery, the 20 experimental mice were randomly placed into treatment groups which received either sterile saline (non-treat group: 10 mg/kg, i.p.) or an anti-NGF antibody (anti-NGF group: 10 mg/kg, i.p.). Simultaneously, all mice received fluorogold (FG) retrograde neurotracer injection into their right joints. In a behavioral study, we evaluated gait using the CatWalk quantitative gait analysis system before surgery, 3 weeks after surgery (before treatment), 4 weeks after surgery (one week after surgery), and 5 weeks after surgery (2 weeks after surgery). In immunohistochemical analysis, the right dorsal root ganglia (DRGs) from the L4–L6 levels were resected 5 weeks after surgery (2 weeks after surgery). They were immunostained for calcitonin gene-related peptide (CGRP), and the number of FG-labeled or CGRP-immunoreactive (IR) DRG neurons was counted.

Results: On gait analysis using the CatWalk system, duty cycle, swing speed, and print area were decreased in non-treat group compared with those in control group and improved in the anti-NGF group compared with those in non-treat group. CGRP expression in DRGs was up-regulated in non-treat group compared with that in control group and suppressed in the anti-NGF group compared with that in non-treat group (both p < 0.05).

Conclusions: MIA injection into the knee joint induced gait impairment and the up-regulation of CGRP in DRG neurons in a knee OA pain model in mice. Intraperitoneal injection of anti-NGF antibody suppressed this impairment of gait and up-regulation of CGRP in DRG neurons. These finding suggest that anti-NGF therapy might be valuable in the treatment of OA pain in the knee.

Keywords: Nerve growth factor, Anti-nerve growth factor therapy, Knee osteoarthritis, Monoiodoacetate, CatWalk, Calcitonin gene-related peptide, Dorsal root ganglia
Background

Knee osteoarthritis (OA) is a common chronic degenerative disease characterized by degeneration of articular cartilage components, synovitis, remodeling of subchondral bone and atrophy of joint muscles. Knee OA patients usually suffer from knee pain and are treated with several treatment modes, including medication, intraarticular injection of hyaluronic acid, and surgery [1]. Understanding of the mechanism of knee OA pain is incomplete, and medication for knee OA pain were sometimes insufficient.

As part of studies into new targets of knee OA pain, we have focused on pain-related molecules, including nerve growth factor (NGF) [2]. NGF not only plays an important role in the maintenance and development of the sensory nervous system [3] but is also a major contributor to inflammation and nociception [4]. Lewin et al. reported that the systemic injection of NGF induced thermal and mechanical hyperalgesia [5]. In addition, systemic injection of anti-NGF antibody reduced allodynia and hyperalgesia in animal models of neuropathic pain, including nerve trunk or spinal nerve ligation [6–8].

Basic research into knee OA has been aided by the development of several animal models, including the anterior cruciate ligament transection model [9], destabilization of the medial meniscus model [10], the rat medical meniscal tear model [11], GDF5 deficiency mice [12], and monooiodoacetate (MIA) injection model [13–16]. The MIA injection model has been reported to result in progressive joint damage, with some features that may be considered similar to OA [14–16] and significant pain-related behavior [13, 16]. The MIA injection model is superior for evaluating knee pain; although it seems animal models including the medical meniscus model better approximate the anatomic pathology found in OA in humans. Some of these previous reports evaluated pain-related behavior using the von Frey test, which is for evaluation of mechanical allodynia. Clinically, however, knee OA patients suffer from knee pain that includes gait impairment but not mechanical allodynia. Several authors have evaluated knee pain behavior using weight bearing assays [17–20]. For instance, the CatWalk gait analysis system can provide quantitative assessment of gait and motor function in rats and mice. This system has recently been used to assay impaired gait function in knee OA pain models [17–19]. Regarding the pathological mechanism of knee OA pain, our previous immunohistochemical analysis showed that the expression of pain-related molecules in the sensory nervous system was increased in a knee OA pain model [16]. Thus, this finding demonstrated the up-regulation of pain-related molecules in the sensory nervous system in the pain state.

We therefore hypothesized that anti-NGF therapy was effective for knee pain in a mouse model of knee OA. The aim of the current study is to evaluate the efficacy of NGF antibody in a knee OA pain model using the CatWalk gait analysis system and immunohistochemical analysis of the sensory nervous system in mice.

Method

Knee osteoarthritis pain model

Thirty 8-week-old male C57 BL/6 mice were used. (Control group: n = 10, Monoiodoacetate (MIA) without treatment (non-treat) group: n = 10, and MIA + anti-NGF therapy (anti-NGF) group: n = 10) Animals were anesthetized with sodium pentobarbital (40 mg/kg, intraperitoneal) and treated aseptically throughout the experiments. In the non-treatment group and anti-NGF group, the right knees were treated with a single intraarticular injection of 0.2 mg of MIA (Sigma-Aldrich, St. Louis, MO) in 10 μl of sterile saline. The solution was injected through the patellar ligament by using a 27G needle with the leg flexed at a 90 degrees angle at the knee as described previously [16]. Three weeks after surgery, mice were randomly assigned to treatment groups receiving either sterile saline (10 mg/kg, i.p.) (non-treat group) or an anti-NGF antibody (L148 M; Exalpha Biological Inc., Shirley, MA) (10 mg/kg, i.p.) (anti-NGF group). We have previously confirmed this medication’s efficacy for treating neuropathic pain [2]. Simultaneously, to detect dorsal root ganglia (DRG) neurons innervating the right knee joint, the right knees of all 20 animals were treated with intraarticular injection of 2% retrograde neurotracer FG (Fluorochrome, Denver, CO) as we have previously described [16]. The control group was treated with a single intraarticular injection of 10 μl of sterile saline to the right knee, followed three weeks later by intraarticular injection of 2% retrograde neurotracer FG.

Behavioral evaluation (gait analysis)

Gait was analysed in detail using the CatWalk system (Noldus Information Technology, Wageningen, The Netherlands). This system has been described in detail elsewhere [19]. Briefly, mice are placed on a glass plate located in a darkened room and allowed to walk freely. A light beam from a fluorescent lamp is aimed through the glass plate. The light beams are completely reflected internally. However, when a paw touches the glass plate, the light beams are reflected downwards. This results in a sharp bright image of the paw print. The entire run is recorded with a video camera. The data are acquired, compressed, and analyzed using CatWalk software as described previously [21].

Before surgery and 3 (before treatment; pre-treat) 4, or 5 weeks (1 or 2 weeks after treatment, respectively; treat-1w or treat-2w) after surgery, all mice were walked on the glass plate three times. The gait of all mice was...
recorded three times and analyzed using the CatWalk system. We compared the ratio of movement of the ipsi and contralateral hind paws with regard to three variables, namely duty cycle (standing as a percentage of the step cycle: stand/(stand time + swing time) × 100%); swing speed (speed of the paw during swing: stride length/swing time); and print area (surface area of the complete print) among the three groups.

**Immunohistochemical analysis**

All procedures, including anesthetization, perfusion, sectioning, immunostaining, and the observation and evaluation of immunoreactive neurons, were used the same manner as described previously [21, 22].

In all three groups, four \( (n = 5, \text{each}) \) or five \( (n = 5, \text{each}) \) weeks after surgery (one to two weeks after treatment), mice were anesthetized with sodium pentobarbital (40 mg/kg, intraperitoneal) and perfused transcardially with 0.9% saline, followed by 30 mL of 4% paraformaldehyde in phosphate buffer (0.1 M, pH 7.4). Next, the right DRGs from the L3 to L5 levels were resected and the specimens were immersed in the same fixative solution overnight at 4 °C, and then stored in 0.01 M phosphate-buffered saline (PBS) containing 20% sucrose for 20 h at 4 °C.

For DRGs, each ganglion was sectioned at a \( 10 \mu \text{m} \) thickness on a cryostat and mounted on POLY-L-LYSINE-coated slides. Endogenous tissue peroxidase activity was quenched by soaking sections in 0.3% hydrogen peroxide solution in 0.01 M PBS for 30 min. Specimens were then treated for 90 min at room temperature in blocking solution consisting of 0.01 M PBS containing 0.3% Triton X-100 and 3% skim milk. To evaluate the expression of neuropeptides in DRGs, the sections were processed for CGRP immunohistochemistry using a rabbit antibody to CGRP (1:1000; Chemicon, Temecula, CA) diluted in blocking solution, and incubated for 20 h at 4 °C. To detect CGRP in the DRGs, sections were incubated for 3 h with goat antirabbit Alexa 488 fluorescent antibody conjugate (1:400; Molecular Probes, Eugene, OR).

Thirty sections in each group (two sections per each DRG (L3, L4, L5) in 5 animals) were examined using a fluorescence microscope. For each DRG section, we counted the number of all Fluoro-Gold-labeled neurons and the number of Fluoro-Gold-labeled and CGRP-immunoreactive (IR) neurons per 0.45 mm\(^2\) in 10 randomly-selected fields among 30 sections in each group at \( \times400 \) magnification using a counting grid, as we have previously reported [16]. The proportion of FG-labeled and CGRP-IR DRG neurons among all FG-labeled DRG neurons was then calculated. All FG-labeled neurons indicated neurons innervating the right knee joint, while FG-labeled and CGRP-IR neurons indicated pain-related neurons innervating the right knee joint.

**Statistical analysis**

Using the ratio of ipsi and contralateral hind paw values for the three CatWalk variables of duty cycle, swing speed, and print area, the proportion of FG-labeled and CGRP-IR DRG neurons among all FG-labeled DRG neurons was compared among the three groups using a non-repeated measures ANOVA with Bonferroni’s correction. A \( p \)-value less than 0.05 was considered statistically significant.

**Results**

**Behavioral analysis**

In the non-treatment group, the ratio of ipsi to contralateral hind paw values for duty cycle was significantly decreased at pre-treat, treat-1w, and treat-2w compared with that in control group, \( (p < 0.05) \) In contrast, in the anti-NGF group, the ratio of ipsi to contralateral hind paws values for duty cycle were significantly decreased only at pre-treat \( (p < 0.05) \) compared with that in control group, and not at treat-1w and treat-2w \( (p > 0.05) \). In addition, the ratio in the anti-NGF group was significantly improved at treat-1w compared with that in the non-treat group, \( (p < 0.05) \) (Fig. 1).

In the non-treated group, the ratio of ipsi to contralateral hind paw values for swing speed were significantly decreased at pre-treat, treat-1w, and treat-2w compared with that in the control group, \( (p < 0.05) \) In contrast, in the anti-NGF group, this ratio was significantly decreased only at pre-treat \( (p < 0.05) \) compared with that in the control group, \( (p < 0.05) \) In contrast, in the anti-NGF group, this ratio was significantly decreased only at pre-treat \( (p < 0.05) \) compared with that in the control group, \( (p < 0.05) \).
in control group, and not at treat-1w and treat-2w ($p > 0.05$). In addition, this ratio in the anti-NGF group was significantly improved at treat-1w compared with that in the non-treat group ($p < 0.05$) (Fig. 2).

In the non-treated group, the ratio of ipsi and contralateral hind paw values for print area were significantly decreased at pre-treat, treat-1w, and treat-2w compared with that in control group ($p < 0.05$). In contrast, in the anti-NGF group, this ratio was significantly decreased only at pre-treat ($p < 0.05$) compared with that in control group, and not at treat-1w and treat-2w ($p > 0.05$). In addition, the ratio in the anti-NGF group was significantly improved at treat-1w and treat-2w compared with that in the non-treat group ($p < 0.05$) (Fig. 3).

**Immunohistochemical analysis**

FG-labeled DRG neurons, which indicated where FG was transported from the right knee, were present in the right L3 to L5 DRGs in all 3 groups (Fig. 4).

The proportion of FG-labeled/CGRP-IR neurons among all FG-labeled neurons was significantly increased in the non-treated group at treat-1w and treat-2w compared with that in control group ($p < 0.05$). Conversely, the expression of CGRP was significantly decreased in the anti-NGF group at treat-1w and treat-2w compared with the non-treated group ($p < 0.05$). (Figs. 4 and 5).

**Discussion**

In this study, intraarticular injection of MIA to the knee joints induced gait disturbances, including a small duty cycle, small swing speed, and small print area, and the up-regulation of neuropeptides in DRG neurons innervating the knee joints. Systemic injection of anti-NGF antibody improved these gait disturbances and the expression of neuropeptides in DRG neurons in this model.

Regarding the Knee OA model, multiple authors have reported various surgery-induced animal models. Myers et al. reported that anterior cruciate ligament transection induced changes in the articular cartilage of the unstable knee that are consistent with OA [23]. In addition, Marijnissen et al. reported the usability of the “Groove” model, in which knee articular cartilage is damaged as a knee OA model [24]. Further, Bendele AM report that meniscal tear in rats results in rapidly progressive degenerative changes to the cartilage with similarities to OA [11]. These surgically induced knee OA models are suitable for basic research, to the extent that they simulate clinical situations. Nevertheless, the MIA injection model which results in severe joint damage seems superior for evaluating knee pain. MIA injection to the knee joints has been reported to cause joint pathology via the inhibition of glycolysis, and thereby targets avascular cartilage and causes chondrocyte death [25]. We also previously reported that MIA-treated knees exhibited behavioral disturbances within four days and osteoarthritic histological
changes within four weeks [16]. We therefore used the MIA injection model as a knee OA model in this study.

Regarding knee pain behavior, several authors reported that knee pain models exhibited mechanical allodynia using the von Frey test [13, 16]. In addition, Shelton DL et al. report NGF induced mechanical allodynia in autoimmune arthritis [26]. Therefore, evaluating knee pain using the von Frey test seems to be appropriate for basic research using animal models. However, there is doubt about whether these models of knee pain simulate clinical situations, because knee OA patients do not typically complain of mechanical allodynia in their foot. Recently, gait analysis studies have focused on behavioral studies to evaluate pain behavior. The CatWalk system was initially developed to evaluate motor function, such as that modified in a spinal cord injury model, a Parkinson’s disease model, or an olivocerebellar degeneration model [19, 27–29]. Recently, this system has been applied to various models to evaluate behavior associated with pain, such as mechanical allodynia models [30]. We also previously evaluated low back pain behavior using the CatWalk system, and concluded that rat models of low back pain exhibit changes in rat gait, including a long standing time and short strides [21, 31]. Recently several authors applied the CatWalk system to evaluate behavior associated with knee pain. Ferland et al. reported that the MIA-induced knee pain model shows gait changes, including a short Duty cycle and a small Swing Speed. In our previous preliminary study, the MIA-induced knee pain model exhibited a small duty cycle, small swing speed, and small print area. (un-published date) Therefore, in this study, we compared the ratio of ipsi and contralateral hind paw values for the three variables, namely duty cycle, swing speed, and print area among the three groups to evaluate the effect of anti-NGF therapy.

Regarding the up-regulation of CGRP in the sensory nervous system, we previously evaluated potential pain-like states by evaluating the up-regulation of pain-related neuropeptides such as CGRP and substance P in the sensory nervous system using a combination of immunohistochemistry and retrograde tracing instead of evaluating pain behavior [22]. CGRP-IR DRG neurons have been reported to be NGF-dependent DRG neurons involved in pain perception related to inflammation [32], suggesting that CGRP is a marker of inflammatory pain. We previously reported that MIA injection to the knee joint induced the up-regulation of CGRP in DRGs [16]. These results suggest that the animals in the group receiving MIA injection to their knee joints were in a state of knee pain.

We focused on NGF as target for the treatment for knee OA pain based on our previous report that MIA injection induced the up-regulation not only inflammatory cytokines but also NGF in the knee joints [16]. Regarding the efficacy of anti-NGF therapy for knee OA pain, NGF is generally involved in chronic inflammatory or neuropathic pain states [33]. Several basic and clinical research had been reported the efficacy of anti-NGF
therapy for knee OA pain [34, 35]. However, the pathological mechanism of knee OA pain was not fully understood. NGF is physically produced in articular structures and expressed in both normal and OA synovial tissues, but is increased in synovial inflammation, especially upon synovial tissue exposure to inflammatory cytokines including TNF-alpha [36, 37]. Thus, the up-regulation of inflammatory cytokines in OA knee joints promoted NGF production, which induced the up-regulation of CGRP in the sensory nervous system and chronic inflammatory or neuropathic pain states. Ashraf S et al. report that NGF injection into knee OA joints results in gait disturbance as compared to NGF injection into non-OA joints. This group used two models of knee OA, including an MIA injection model and a meniscal transection model [38]. Further, McNamee KE et al. report NGF expression is correlated with knee pain but that TNF alpha is not up-regulated in the late stages of OA [39]. These findings indicate inflammatory cytokines including TNF might only develop during the pain state, but that NGF might play a role in maintaining as well as in development of the pain state in knee OA patients. Therefore, NGF represents a possible important therapeutic target in the treatment of knee OA pain. In preclinical studies, newly developed tanezumab and its murine precursor muMab-911 have effectively targeted the NGF pathway in various chronic and inflammatory pain models [40]. In addition, phase I and II clinical trials for osteoarthritis pain and chronic lower back pain have demonstrated efficacy for the compound, as well as a good safety and tolerability profile [41]. In the present study, anti-NGF therapy suppressed the impairment gait and up-regulation of CGRP in DRG neurons. These findings may explain the pathological mechanism of knee OA pain.

There were some limitations in this study. First, we should have used tanezumab and its murine precursor muMab-911 for this study. We also did not evaluate differences in efficacy between muMab-911 and anti-NGF antibody, which we used in this study. Second, we did not evaluate the efficacy of positive control including non-steroid anti-inflammatory drugs for knee OA pain. Third, we also evaluated the efficacy of only a one-time injection of anti-NGF antibody. In the future, it will be necessary to evaluate the effect of repeated injections for knee pain. Fourth, we did not evaluate the histopathology of the knee joint. In clinical trials of the monoclonal NGF antibody tanezumab for knee and hip OA pain, osteonecrosis was reported as a side effect [42]. Therefore, further study focusing on side effects of anti-NGF therapy is necessary. Fifth, we did not include a power calculation to justify the group sizes. Further, due to ethical concerns related to using the animals, we combined our behavioral and immunohistochemical evaluations. Therefore, with regard to behavioral evaluation, some experiments ended after 4 weeks and others ended after 5 weeks.

Conclusions
MIA injection into the knee joint induced gait impairment and the up-regulation of CGRP in DRG neurons in a knee OA pain model in mice. Further, intraperitoneal injection of anti-NGF antibody suppressed gait impairment and the up-regulation of CGRP in DRG neurons. These findings indicate that anti-NGF therapy might be valuable in the treatment of OA pain in the knee.

Abbreviations
CGRP: Calcitonin gene related peptide; DRG: dorsal root ganglion; FG: FluoroGold; IR: immunoreactive; MIA: monoiodeacetate; NGF: nerve growth factor; OA: osteoarthritis

Acknowledgments
Not applicable.

Funding
MM was supported by Mitsui Sumitomo Insurance Welfare Foundation.

Availability of data and materials
The datasets used and analysed during the current study available from the corresponding author on reasonable request.

Authors’ contributions
MM conceived this study and carried out the behavioral studies and immunohistochemical studies, participated in its design and coordination and drafted the manuscript; TI carried out behavioral studies and immunohistochemical studies and drafted the manuscript; HK MS and GI made animal models and helped to revise the manuscript; YS, YO, SO carried out behavioral studies and participated in the design of the study; KU carried out statistical analysis and revised the manuscript; KT and MT participated in the design of the study and SO conceived the study and participated in its design and coordination. All authors have read and approved the final manuscript.

Ethics approval and consent to participate
All protocols for animal procedures were approved by the Ethics Committees of Chiba University following the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals (1996 revision).

Consent for publication
Not applicable.

Competing interests
This work was supported by Mitsui Sumitomo Insurance Welfare Foundation. The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Orthopaedic Surgery, Kitasato University, School of Medicine, 1-15-1, Kitasato, Minami-ku, Sagamihara city, Kanagawa 252-0374, Japan.
2Department of Orthopaedic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
both prevents and reverses pain behaviour and subchondral osteoclast numbers in a rat model of osteoarthritis pain. Osteoarthritis. Cartilage. 2016; 24(9):1587–95.

41. Cattaneo A. Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain. Curr.Opin.Mol. Ther. 2010;12(1):94–106.

42. Balanescu AR, Feist E, Wolfram G, Davignon J, Smith MD, Brown MT, West CR. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial. Ann.Rheum.Dis. 2014;73(9):1665–72.